计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| C413899-5mg |
5mg |
现货 ![]() |
| |
| C413899-10mg |
10mg |
现货 ![]() |
| |
| C413899-25mg |
25mg |
现货 ![]() |
| |
| C413899-50mg |
50mg |
现货 ![]() |
| |
| C413899-100mg |
100mg |
现货 ![]() |
|
| 英文别名 | 2,8-Diazaspiro[4.5]decan-1-one,8-[3-chloro-5-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]-4-pyridinyl]- |
|---|---|
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | CCT251545 |
| 生化机理 | CCT251545 是一种口服生物活性强的 WNT 信号转导抑制剂,在 7dF3 细胞中的 IC50 为 5 nM。CCT251545 还是一种选择性化学探针,可用于探索 CDK8 和 CDK19 在人类疾病中的作用。 |
| 储存温度 | -20°C储存,充氩 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 细胞周期蛋白依赖性激酶 19 抑制剂;细胞周期蛋白依赖性激酶 8 抑制剂 |
| 产品介绍 |
Information CCT251545 CCT251545 is a potent, orally bioavailable inhibitor of WNT signaling with IC50 of 5 nM in 7dF3 cells. CCT251545 also act as a selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Targets CDK8 ; CDK19 ; Wnt (in 7dF3 cells) ; 5 nM In vitro The suppression of the WNT pathway activity by CCT251545 is not unique to a specific cell line, is independent of exogenous WNT pathway stimulation, does not result from destabilization of TCF1 or TCF4, and is not due to interference with the luciferase-based reporter readout. CCT251545 also demonstrates a lack of transporter-mediated efflux and a lack of activity across broad in vitro panels of enzyme, receptor, and ion channel targets. In vivo CCT251545 is a potent small-molecule inhibitor of WNT signaling with good oral pharmacokinetics. We demonstrate inhibition of WNT pathway activity in a solid human tumor xenograft model with evidence for tumor growth inhibition following oral dosing. Cell Research(from reference) Cell lines:7dF3 cells, HEK293 cells, SW480, LS174T, COLO205 human colorectal cancer cells Concentrations:9.1 μM - 0.068 nM Incubation Time:2 h, 6 h |
| 纯度 | ≥99% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 8-[3-chloro-5-[4-(1-methylpyrazol-4-yl)phenyl]pyridin-4-yl]-2,8-diazaspiro[4.5]decan-1-one |
| INCHI | 1S/C23H24ClN5O/c1-28-15-18(12-27-28)16-2-4-17(5-3-16)19-13-25-14-20(24)21(19)29-10-7-23(8-11-29)6-9-26-22(23)30/h2-5,12-15H,6-11H2,1H3,(H,26,30) |
| InChi Key | LBFYQISQYCGDDW-UHFFFAOYSA-N |
| Smiles | CN1C=C(C=N1)C2=CC=C(C=C2)C3=CN=CC(=C3N4CCC5(CCNC5=O)CC4)Cl |
| Isomeric SMILES | CN1C=C(C=N1)C2=CC=C(C=C2)C3=CN=CC(=C3N4CCC5(CCNC5=O)CC4)Cl |
| MeSH Entry Terms | 8-(3-chloro-5-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)pyridin-4-yl)-2,8-diazaspiro(4.5)decan-1-one;CCT251545 |
| 分子量 | 421.92 |
| Reaxy-Rn | 28916227 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=28916227&ln= |
| 溶解性 | Solubility (25°C) In vitro DMSO: 30 mg/mL (71.1 mM); Ethanol: 5 mg/mL (11.85 mM); Water: Insoluble; |
|---|---|
| 分子量 | 421.900 g/mol |
| XLogP3 | 2.900 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 4 |
| 可旋转键计数Rotatable Bond Count | 3 |
| 精确质量Exact Mass | 421.167 Da |
| 单同位素质量Monoisotopic Mass | 421.167 Da |
| 拓扑极表面积Topological Polar Surface Area | 63.100 Ų |
| 重原子数Heavy Atom Count | 30 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 617.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Mallinger A, Crumpler S, Pichowicz M, Waalboer D, Stubbs M, Adeniji-Popoola O, Wood B, Smith E, Thai C, Henley AT et al.. (2015) Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.. J Med Chem, 58 (4): (1717-35). [PMID:25680029] |